Clinical trials: Fasting Glucose
Hyperglycemia, Diabetes Mellitus
Lantus in Prediabetes
To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).
- Trial name
- NCT00348972
- Testing
- Lantus® (insulin glargine)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale.
- Trial name
- NCT03816761
- Testing
- Fast-acting insulin aspart, iLet™
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus (Type 2)
A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions
This study was an open-label, randomized, single-dose, 2-sequence, 2-period, crossover study to evaluate the safety and pharmacokinetics of UI087 compared to coadministration of UIC202506, UIC202507 and UIC202508 in healthy adult…
- Trial name
- NCT07548957
- Testing
- Administration of UI087, Administration of UIC202506, UIC202507, UIC202508
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Korea United Pharm. Inc.
ASCVD, Impaired Fasting Glucose
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and hypertension.
- Conditions
- ASCVD, Impaired Fasting Glucose, Hypertension
- Trial name
- NCT03474562
- Testing
- Duowell®, Monorova® + Amlopin®
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Yuhan Corporation
Healthy
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of SIPS-2209-1 in Healthy Korean Volunteers
The goal of this clinical trial is to evaluate of bioequivalence between fixed-dose combination and co-administration of the individual components under fasting conditions in healthy Korean volunteers.
- Trial name
- NCT05787873
- Testing
- SIPS-2209-1, SIPS-2209-2, SIPS-2209-3
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Samik Pharmaceutical Co. Ltd.
Impaired Fasting Glucose
Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose
The Purpose of this study is to compare the effects of 2 types of dietary fiber, psyllium and microcrystalline cellulose (MCC), on glycemic measures in subjects with impaired fasting glucose.
- Trial name
- NCT01549600
- Testing
- psyllium, Microcrystalline Cellulose
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Diabetes Mellitus, Type 2
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
Primary Objective: To compare the safety, in terms of percentage of patients with symptomatic documented hypoglycemia during Ramadan fast, of lixisenatide versus sulfonylurea (SU).
- Trial name
- LixiRam (NCT02941367)
- Testing
- Lixisenatide (AVE0010), Sulfonylurea, metformin
- Where
- 16 sites in India, Israel and 2 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT02496221
- Testing
- Albiglutide 50 mg, CCK (Kinevac)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily…
- Trial name
- NCT00449553
- Testing
- Pioglitazone and sulphonylurea, Pioglitazone and metformin
- Where
- 4 sites in Denmark, Iceland and 2 more
- Volunteers
- 326 people
- Sponsor
- Takeda
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetes Mellitus Type 2
A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.
This study will assess the efficacy, safety and tolerability of increasing doses of GK Activator (2) in patients with type 2 diabetes whose condition has not been optimally controlled with one previous oral antihyperglycemic…
- Trial name
- NCT00366379
- Testing
- GK Activator (2)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal.
- Trial name
- GBGT (NCT07313813)
- Testing
- Dulaglutide
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Screening for Early Evidence of Diabetes
This is a pivotal study to determine the accuracy of a new device (SCOUT) in screening persons for pre-diabetes or diabetes. SCOUT will be compared to the standard screening test (Fasting Plasma Glucose), using the Oral Glucose…
- Trial name
- SEED (NCT00614783)
- Where
- 15 sites in United States
- Volunteers
- 3,478 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Diabetes Mellitus Type 2
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.
- Trial name
- FPG-VISIT (NCT01398592)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 15 sites in Germany
- Volunteers
- 187 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus Type 1
Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate
This is a pilot trial to establish study procedures that allow comparison of various starting basal rate profiles used in Continuous Subcutaneous Insulin Infusion (CSII).
- Trial name
- NCT00569452
- Testing
- Accu-Chek Spirit Insulin Pump
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
HbA1c Level Associated With Lipid Compositions
to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting…
- Trial name
- SIPHON (NCT02056847)
- Testing
- Pitavastatin calcium 4mg, Pitavastatin calcium 2mg
- Where
- South Korea
- Volunteers
- 313 people
- Sponsor
- JW Pharmaceutical
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting…
- Trial name
- NCT06890286
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes
Distinguishing Participant Groups Using Autonomic Dysfunction
A study population with impaired fasting glucose levels, impaired glucose tolerance levels and diabetes (with or without complications) along with healthy patients will be chosen as participants.
- Trial name
- NCT05199350
- Testing
- Device Name: ANSiscope
- Where
- India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- DyAnsys, Inc.
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR…
- Trial name
- NCT03138356
- Testing
- 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- AstraZeneca